Novus International Inc. and biotechnology company Verenium Corporation have partnered to develop and commercialize animal nutrition enzymes targeting the poultry, swine, beef, dairy and aquaculture markets.

The partnership, which will include equal shares in representation, costs and profits for both companies, will allow Verenium to "become a more active participant in the animal health and nutrition marketplace," said James Levine, president and CEO of Verenium.

Novus expects to benefit from an expanded product line. “Our partnership with Verenium will allow us to work together to develop and commercialize a suite of new enzyme products for the global animal nutrition and health market,” said Thad Simons, Novus president and CEO. “These new enzyme products will give us the ability to offer new solutions to the performance challenges our customers face.”

Once introduced to the marketplace, all products will be co-branded by Novus and Verenium.